HOME
PROJECTS
MEMBERS
JOURNAL
CONTACT
O'Shaughnessy's
Home
This
Issue Home
|
Autumn 2005
O'Shaughnessy's
Journal of the California Cannabis Research Medical
Group
|
Case Note:
Extreme Sensitivity to Marinol
A married 51-year-old male computer scientist with severe
migraines for some 16 years experienced serious adverse effects from
conventional treatments of Immitrex, Maxalt, amitriptyline, antivert;
lives in a state with no legal access to medical marijuana; discovered
that small amounts of Marinol would control his headaches. (And concurrently
his irritable bowel syndrome as well.) Sensitive to most medications,
he discovered cannabis to be efficacious without adverse effects. Because
of its illegal status, Marinol (dronabinol) was begun. The 2.5 mg dose
would put him to sleep and he would wake up feeling stoned. So he took
to extracting a quarter of the 2.5 milligram dose with a needle. That
worked for a couple of years but now he’s developed sensitivity
even to the lower dose. He’s tried discontinuing on several occasions
times but the migraines return. Suggested that the patient explore
the legality of obtaining Sativex through Canada.
I contacted the regional representative from Solvay, who will forward
this case report to their medical department. The preparation of dronabinol
of lesser concentration might solve the problem. The other possibility
is an inhaled preparation for finer titration. Solvay is working on
this, I was told by the representative.
—Tod Mikuriya, MD
|
O'Shaughnessy's
is the journal of the CCRMG/SCC. Our primary goals are the same
as the stated goals of any
reputable scientific publication: to bring out findings that are
accurate, duplicable, and useful to the community at large. But in
order to do this, we have to pursue parallel goals such as removing
the impediments to clinical research created by Prohibition, and
educating our colleagues, co-workers and patients as we educate ourselves
about the medical uses of cannabis.
|
The Society
of Cannabis Clinicians (SCC) was formed in the Autumn of 2004 by
the member physicians of CCRMG
to aid in the promulgation of voluntary standards for clinicians
engaged in the recommendation and approval of cannabis under California
law (HSC §11362.5).
As the collaborative effort continues to move closer to issueing
guidelines, this site serves as a public venue for airing and
discussing these guidelines.
Visit the SCC Site for more information.
|
|